Trials / Completed
CompletedNCT05624944
A Pharmacokinetic Study of TS-142 in Patients with Hepatic Impairment
An Open-label Pharmacokinetic Study of TS-142 in Patients with Hepatic Impairment
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 84 (actual)
- Sponsor
- Taisho Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Accepted
Summary
This is an open-label pharmacokinetic study of TS-142 in patients with hepatic impairment
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TS-142 5 mg | Single-dose of 5 mg of TS-142 |
Timeline
- Start date
- 2022-12-26
- Primary completion
- 2023-12-05
- Completion
- 2023-12-05
- First posted
- 2022-11-22
- Last updated
- 2025-02-28
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT05624944. Inclusion in this directory is not an endorsement.